CAPR News and Press, Capricor Therapeutics Inc. From 03/11/21

Exosomes Platform Technology -Pre-IND Meeting with FDA this Quarter to Discuss Multivalent Exosome-mRNA Vaccine- -Pipeline Expansion Underway Using Engineered Exosomes- Cell Therapy Program -In Discussions with FDA on Pathway to Approval for Duchenne Muscular Dystr...

Capricor Therapeutics (CAPR) announces new advances from its positive preclinical study for a multivalent exosome-based mRNA vaccine for COVID-19 have been posted and has been submitted for publication.Data showed that exosome-mRNA formulations can drive functional enzyme expression ...

-New Data Demonstrates Exosome-Mediated Delivery of mRNAs With Enhanced Expression and Lower Toxicity Compared to Lipid Nanoparticles- -Functional Enzyme Expression and Real-Time Imaging of mRNA Expression in Live Animals- -Platform for Advancing Clinical Development of Exosome-RN...

LOS ANGELES, March 04, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the development of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders will release its ...

Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and impacts approximately six per 100,000 individuals in North America and Europe. Current treatments are inadequate because they only address a small segment of the Duchenne muscular dy...

Clinical-stage biotech Capricor Therapeutics ([[CAPR]] +5.6%) has received a non-exclusive license to intellectual property, know-how and data related to a new imaging-based serology test platform for COVID-19 from Johns Hopkins University.This platform has been applied to the analy...

-Technology Licensed from Johns Hopkins University- -Patient Data Demonstrates Validity of Novel Imaging-Based Approach Furthering Capricor’s Platform Advancement- LOS ANGELES, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stag...

Gainers: Oxbridge Re (OXBR) +62%.Koss (KOSS) +60%.AIkido Pharma (AIKI) +51%.Vertex Energy (VTNR) +56%.Phunware (PHUN) +45%.Edesa Biotech (EDSA) +33%.CarParts.com (PRTS) +32%.Workhorse Group (WKHS) +30%.Orbital Energy (OEG) +27%.Vir Biotechnology (VIR) +27%.Losers: Express ...

Gainers: Vir Biotechnology VIR +39%, AIkido Pharma (AIKI) +37%, Edesa Biotech EDSA +34%, Motus GI Holdings (MOTS) +29%, Regional Health Properties (RHE) +24%.Losers: Lipocine (LPCN) -18%, Capricor Therapeutics (CAPR) -17%, Iterum Therapeutics ...

Capricor Therapeutics ([[CAPR]] +10.8%) announces findings from collaboration with researchers at Cedars-Sinai Medical Center, which demonstrates the utility of pathway-enhancing culture conditions and small molecule inhibitors to retain markers of cell therapy potency.Capricor's lead candida...